Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by mercedesmanon Jan 12, 2023 4:09pm
290 Views
Post# 35219516

Summary of today...

Summary of today...Pace of enrollment still sucks


the "market"  (actually the sum of all holders of Spectral shares which is a poor proxy for a market) does not appear to be very concerned. (see unchanged SP and low volume)

Eden and Euphas-2 results hinted at are very encouraging (increasing the odds of a favourable & eventual FDA ruling ? and perhaps a richer buyout? )

Baxter appears to be laying some great groundwork (increasing odds of ultimate approval? and an eventual "transaction" ?)

Poor enrolment numbers of late, may have been offset by the good news of improved odds of ultimate approval (see EDEN and Euphas 2) -  at least collectively in the minds of the (small) invested population.

"Key Pout" sign at SH still in full vigor...discouraging to a higher SP (mision accomplished?)

Still not buying the "lifestyle" argument.  Very lame.

Hopeful that the BIG investors + Baxter are growiing impatient and will apply the requisite amount of pressure...in order to get things ramped up to a better pace in 2023.  Need more creativity than adding new sites (with all the training and set-up that goes with that)

the BoD should be well prepared to defend/justify any addional performance bonuses/options that may be granted over the next few months.

Have a great day everyone.

MM
<< Previous
Bullboard Posts
Next >>